Key result
Rivaroxaban with or without aspirin in stable cardiovascular disease is discussed in this correspondence responding to the 2017 New England Journal of Medicine publication.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question. Rivaroxaban with or without aspirin in stable cardiovascular disease is discussed in this correspondence responding to the 2017 New England Journal of Medicine publication.
Synapse has enriched 10 related papers. Consider them for comparative context: